Chemours Company is a global leader in chemistry and material science, specializing in the production of a diverse range of industrial solutions. The company focuses on developing innovative products in critical sectors such as advanced performance materials, fluoroproducts, and titanium technologies. Chemours plays a significant role in addressing environmental challenges, offering sustainable solutions that enhance performance while minimizing ecological impact. Their cutting-edge technologies cater to various industries, including electronics, automotive, construction, and manufacturing, aiming to drive progress and improve the quality of everyday life through their specialized chemical products. Read More
NEW YORK CITY, NY / ACCESS Newswire / October 16, 2026 / Levi & Korsinsky, LLP tracks the Chemours analyst downgrade wave on Wall Street as a securities class action proceeds on behalf of investors in The Chemours Company (NYSE:CC) who purchased securities between February 20, 2026 and August 4, 2026. Find out if you could qualify to recover your losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
LOS ANGELES, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Law Offices of Frank R. Cruz reminds investors of the upcoming December 7, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”).
NEW ORLEANS, Oct. 15, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company (“Chemours” or the “Company”) (NYSE: CC), if they purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Delaware.
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against The Chemours Company (“Chemours”) (NYSE: CC) on behalf of those who purchased or acquired Chemours securities between February 20, 2026 and August 4, 2026, inclusive. The lawsuit is filed in the United States District Court for the District of Delaware and is captioned Darcy v. The Chemours Company, No. 1:26-cv-01299 (D. Del.). Investors have until December 7, 2026, to file for lead plaintiff status.
NEW YORK and NEW ORLEANS, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company (“Chemours” or the “Company”) (NYSE: CC), if they purchased or otherwise acquired the Company’s securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Delaware.
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours " or the "Company") (NYSE: CC) and certain officers. The class action, filed in the United States District Court for the District of Delaware, and docketed under 26-cv-01299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE:CC) and certain of the company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company (“Chemours” or the “Company”) (NYSE: CC), if they purchased or otherwise acquired the Company’s securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Delaware.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Chemours Company (“The Chemours” or the “Company”) (NASDAQ: CC) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). Chemours investors have until December 7, 2026 to file a lead plaintiff motion.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) common stock between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). Chemours investors have until December 7, 2026 to file a lead plaintiff motion.
The DJS Law Group reminds investors of a class action lawsuit against The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of persons or entities who purchased or otherwise acquired The Chemours Company (NYSE: CC) securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). Chemours offers a range of industrial and specialty chemical products for markets including, refrigeration and air conditioning.
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) common stock between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). Chemours investors have until December 7, 2026 to file a lead plaintiff motion.
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning the Company’s possible violations of federal securities laws.
Chemours (NYSE:CC) said its second-quarter results reflected pricing gains, operational improvements and continued execution under its Pathway to Thrive strategy, while softer residential air-conditioning aftermarket demand weighed on sales in its Thermal & Specialized Solutions business.
Presi
Chemours (NYSE:CC) said it opened 2026 with first-quarter results that were “well above earnings expectations,” driven by strong execution in its Thermal & Specialized Solutions and Titanium Technologies segments, while Advanced Performance Materials continued to recover from an outage at the co
